Matches in SemOpenAlex for { <https://semopenalex.org/work/W4310828209> ?p ?o ?g. }
- W4310828209 endingPage "139" @default.
- W4310828209 startingPage "131" @default.
- W4310828209 abstract "Type 2 circulating vaccine-derived polioviruses (cVDPV2) from Sabin oral poliovirus vaccines (OPVs) are the leading cause of poliomyelitis. A novel type 2 OPV (nOPV2) has been developed to be more genetically stable with similar tolerability and immunogenicity to that of Sabin type 2 vaccines to mitigate the risk of cVDPV2. We aimed to assess these aspects of nOPV2 in poliovirus vaccine-naive newborn infants.In this randomised, double-blind, controlled, phase 2 trial we enrolled newborn infants at the Matlab Health Research Centre, Chandpur, Bangladesh. We included infants who were healthy and were a single birth after at least 37 weeks' gestation. Infants were randomly assigned (2:1) to receive either two doses of nOPV2 or placebo, administered at age 0-3 days and at 4 weeks. Exclusion criteria included receipt of rotavirus or any other poliovirus vaccine, any infection or illness at the time of enrolment (vomiting, diarrhoea, or intolerance to liquids), diagnosis or suspicion of any immunodeficiency disorder in the infant or a close family member, or any contraindication for venipuncture. The primary safety outcome was safety and tolerability after one and two doses of nOPV2, given 4 weeks apart in poliovirus vaccine-naive newborn infants and the primary immunogenicity outcome was the seroconversion rate for neutralising antibodies against type 2 poliovirus, measured 28 days after the first and second vaccinations with nOPV2. Study staff recorded solicited and unsolicited adverse events after each dose during daily home visits for 7 days. Poliovirus neutralising antibody responses were measured in sera drawn at birth and at age 4 weeks and 8 weeks. This study is registered on ClinicalTrials.gov, NCT04693286.Between Sept 21, 2020, and Aug 16, 2021, we screened 334 newborn infants, of whom three (<1%) were found to be ineligible and one (<1%) was withdrawn by the parents; the remaining 330 (99%) infants were assigned to receive nOPV2 (n=220 [67%]) or placebo (n=110 [33%]). nOPV2 was well tolerated; 154 (70%) of 220 newborn infants in the nOPV2 group and 78 (71%) of 110 in the placebo group had solicited adverse events, which were all mild or moderate in severity. Severe unsolicited adverse events in 11 (5%) vaccine recipients and five (5%) placebo recipients were considered unrelated to vaccination. 306 (93%) of 330 infants had seroprotective maternal antibodies against type 2 poliovirus at birth, decreasing to 58 (56%) of 104 in the placebo group at 8 weeks. In the nOPV2 group 196 (90%) of 217 infants seroconverted by week 8 after two doses, when 214 (99%) had seroprotective antibodies.nOPV2 was well tolerated and immunogenic in newborn infants, with two doses, at birth and 4 weeks, resulting in almost 99% of infants having protective neutralising antibodies.Bill & Melinda Gates Foundation." @default.
- W4310828209 created "2022-12-19" @default.
- W4310828209 creator A5001513342 @default.
- W4310828209 creator A5003663640 @default.
- W4310828209 creator A5010655685 @default.
- W4310828209 creator A5012158992 @default.
- W4310828209 creator A5014653789 @default.
- W4310828209 creator A5017519148 @default.
- W4310828209 creator A5022089682 @default.
- W4310828209 creator A5034235303 @default.
- W4310828209 creator A5041318439 @default.
- W4310828209 creator A5046260344 @default.
- W4310828209 creator A5049688300 @default.
- W4310828209 creator A5052517269 @default.
- W4310828209 creator A5053743726 @default.
- W4310828209 creator A5069087073 @default.
- W4310828209 creator A5088631763 @default.
- W4310828209 date "2023-01-01" @default.
- W4310828209 modified "2023-09-30" @default.
- W4310828209 title "Evaluation of the safety, immunogenicity, and faecal shedding of novel oral polio vaccine type 2 in healthy newborn infants in Bangladesh: a randomised, controlled, phase 2 clinical trial" @default.
- W4310828209 cites W2024279068 @default.
- W4310828209 cites W2072881891 @default.
- W4310828209 cites W2086268875 @default.
- W4310828209 cites W2097965467 @default.
- W4310828209 cites W2107376649 @default.
- W4310828209 cites W2125876252 @default.
- W4310828209 cites W2138819994 @default.
- W4310828209 cites W2414376389 @default.
- W4310828209 cites W2510158554 @default.
- W4310828209 cites W2770032196 @default.
- W4310828209 cites W2899259430 @default.
- W4310828209 cites W2948253547 @default.
- W4310828209 cites W3019697184 @default.
- W4310828209 cites W3022695806 @default.
- W4310828209 cites W3111877257 @default.
- W4310828209 cites W3204557073 @default.
- W4310828209 cites W4254537929 @default.
- W4310828209 cites W4292676078 @default.
- W4310828209 cites W4293064466 @default.
- W4310828209 cites W4296817036 @default.
- W4310828209 doi "https://doi.org/10.1016/s0140-6736(22)02397-2" @default.
- W4310828209 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36495882" @default.
- W4310828209 hasPublicationYear "2023" @default.
- W4310828209 type Work @default.
- W4310828209 citedByCount "7" @default.
- W4310828209 countsByYear W43108282092023 @default.
- W4310828209 crossrefType "journal-article" @default.
- W4310828209 hasAuthorship W4310828209A5001513342 @default.
- W4310828209 hasAuthorship W4310828209A5003663640 @default.
- W4310828209 hasAuthorship W4310828209A5010655685 @default.
- W4310828209 hasAuthorship W4310828209A5012158992 @default.
- W4310828209 hasAuthorship W4310828209A5014653789 @default.
- W4310828209 hasAuthorship W4310828209A5017519148 @default.
- W4310828209 hasAuthorship W4310828209A5022089682 @default.
- W4310828209 hasAuthorship W4310828209A5034235303 @default.
- W4310828209 hasAuthorship W4310828209A5041318439 @default.
- W4310828209 hasAuthorship W4310828209A5046260344 @default.
- W4310828209 hasAuthorship W4310828209A5049688300 @default.
- W4310828209 hasAuthorship W4310828209A5052517269 @default.
- W4310828209 hasAuthorship W4310828209A5053743726 @default.
- W4310828209 hasAuthorship W4310828209A5069087073 @default.
- W4310828209 hasAuthorship W4310828209A5088631763 @default.
- W4310828209 hasBestOaLocation W43108282091 @default.
- W4310828209 hasConcept C126322002 @default.
- W4310828209 hasConcept C142724271 @default.
- W4310828209 hasConcept C159654299 @default.
- W4310828209 hasConcept C187212893 @default.
- W4310828209 hasConcept C197934379 @default.
- W4310828209 hasConcept C203014093 @default.
- W4310828209 hasConcept C204787440 @default.
- W4310828209 hasConcept C22070199 @default.
- W4310828209 hasConcept C2522874641 @default.
- W4310828209 hasConcept C2776494729 @default.
- W4310828209 hasConcept C2777451964 @default.
- W4310828209 hasConcept C2778375690 @default.
- W4310828209 hasConcept C2779631682 @default.
- W4310828209 hasConcept C2780868878 @default.
- W4310828209 hasConcept C4870876 @default.
- W4310828209 hasConcept C71924100 @default.
- W4310828209 hasConceptScore W4310828209C126322002 @default.
- W4310828209 hasConceptScore W4310828209C142724271 @default.
- W4310828209 hasConceptScore W4310828209C159654299 @default.
- W4310828209 hasConceptScore W4310828209C187212893 @default.
- W4310828209 hasConceptScore W4310828209C197934379 @default.
- W4310828209 hasConceptScore W4310828209C203014093 @default.
- W4310828209 hasConceptScore W4310828209C204787440 @default.
- W4310828209 hasConceptScore W4310828209C22070199 @default.
- W4310828209 hasConceptScore W4310828209C2522874641 @default.
- W4310828209 hasConceptScore W4310828209C2776494729 @default.
- W4310828209 hasConceptScore W4310828209C2777451964 @default.
- W4310828209 hasConceptScore W4310828209C2778375690 @default.
- W4310828209 hasConceptScore W4310828209C2779631682 @default.
- W4310828209 hasConceptScore W4310828209C2780868878 @default.
- W4310828209 hasConceptScore W4310828209C4870876 @default.
- W4310828209 hasConceptScore W4310828209C71924100 @default.
- W4310828209 hasIssue "10371" @default.
- W4310828209 hasLocation W43108282091 @default.
- W4310828209 hasLocation W43108282092 @default.